First patient randomised as study advances novel pan phosphate transporter inhibitor R1 Therapeutics has randomized the first ...
Lundbeck has received Fast Track designation from the U.S. FDA for Lu AH69593, its lead oral orexin 2 receptor agonist in ...
Mission Therapeutics has agreed to divest its phase 2‑ready acute kidney injury candidate MTX652 to Australian renal ...
GSK has secured US FDA approval for Jideytro (zidesamtinib) for adults with locally advanced or metastatic ROS1‑positive ...
Jasper Therapeutics has completed its all‑stock acquisition of Kira Pharmaceuticals, creating a combined business focused on ...
The Scottish Medicines Consortium has recommended Astellas’s VEOZA (fezolinetant) 45 mg once daily for the treatment of ...
Nouscom will present new phase 1b/2 data on its off‑the‑shelf cancer immunotherapy NOUS‑209 at the European Society for ...
ViiV Healthcare will present a broad range of clinical and real-world data at AIDS 2026, highlighting progress across its integrase strand transfer inhibitor portfolio, including long-acting medicines ...
EpilepsyGTx has partnered with ClearPoint Neuro to enable targeted delivery of its lead gene therapy candidate, EPY201, ahead ...
Ardena has appointed Ariane de Ganck as Chief Scientific Officer, reinforcing its focus on scientific excellence across its ...
Merck has announced that the European Commission has approved an update to the Erbitux (cetuximab) EU label, extending its ...
Braun has appointed Sophie Spencer as Social Value & ESG Specialist, recognising her rapid impact since joining the company ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results